The European Union’s medicines regulator said on Tuesday that there is a “possible link” between Johnson & Johnson’s COVID-19 vaccine and blood clots, but said its “overall benefit-risk remains positive.” At a meeting on Tuesday, the safety committee of the European Medicines Agency (EMA) concluded that a warning about unusual blood clots should be added to the product information for COVID-19 Vaccine Janssen, which was developed by Janssen, a subsidiary of Johnson & Johnson. The blood clot events should be listed as “very rare side effects” of the vaccine, the committee said. The committee said it took into consideration “all currently available evidence” including eight reports from the United States of serious cases of unusual blood clots associated with low levels of blood platelets, one of which had a fatal outcome. All these cases occurred within three weeks after vaccination in people under 60, most of whom were women. The …